Moleculin Biotech reports a larger-than-expected Q1 GAAP loss of $3.54 per share, missing estimates by $2.08.
Moleculin Biotech posted a Q1 GAAP loss of $3.54 per share, exceeding the expected loss by $2.08. The wider loss reflects ongoing operational costs and investment in development programs.
The company’s cash reserves stood at $10.3 million as of March 31, 2026, with management projecting these funds will sustain operations into the third quarter of 2026. Prior quarter results and consensus estimates were not provided for comparison.
No immediate market reaction was disclosed in the release.